DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Raises Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 40.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,290 shares of the company’s stock after buying an additional 2,086 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in TransMedics Group were worth $455,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in TMDX. Atlas Capital Advisors Inc. bought a new position in TransMedics Group during the 4th quarter worth about $31,000. Hager Investment Management Services LLC bought a new position in shares of TransMedics Group during the fourth quarter valued at approximately $33,000. Sachetta LLC bought a new position in shares of TransMedics Group during the fourth quarter valued at approximately $40,000. AlphaQuest LLC purchased a new position in TransMedics Group during the fourth quarter valued at approximately $52,000. Finally, Arcadia Investment Management Corp MI bought a new position in TransMedics Group in the fourth quarter worth approximately $72,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Up 19.6%

NASDAQ:TMDX opened at $111.50 on Monday. The company’s 50 day moving average is $78.53 and its two-hundred day moving average is $75.10. The company has a market cap of $3.77 billion, a PE ratio of 118.62 and a beta of 1.91. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.35 earnings per share. Analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

TMDX has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a research report on Friday. Canaccord Genuity Group restated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Finally, Oppenheimer increased their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.